(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| contextvision (contx.ol) | kr7.28 | 3.46% | 61.1% |
| eurofins scient. (erf.pa) | €56.30 | 1.83% | 9.12% |
| vetoquinol (veto.pa) | €90.50 | 0.91% | 10.37% |
| virbac (virp.pa) | €271.50 | 0.49% | 15.51% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. contextvision (contx.ol)
3.46% forward dividend yield and 61.1% return on equity
contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and the united states. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary. its products include rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and rivent 3d, an image enhancement product for 3d ultrasound. the company also provides altumira/altumira plus, a platform for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. the company was founded in 1983 and is headquartered in stockholm, sweden.
earnings per share
as for profitability, contextvision has a trailing twelve months eps of kr0.44.
pe ratio
contextvision has a trailing twelve months price to earnings ratio of 16.55. meaning, the purchaser of the share is investing kr16.55 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.
more news about contextvision.
2. eurofins scient. (erf.pa)
1.83% forward dividend yield and 9.12% return on equity
eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and technologies services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.
earnings per share
as for profitability, eurofins scient. has a trailing twelve months eps of €2.28.
pe ratio
eurofins scient. has a trailing twelve months price to earnings ratio of 24.69. meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.12%.
dividend yield
according to morningstar, inc., the next dividend payment is on jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.83%.
more news about eurofins scient..
3. vetoquinol (veto.pa)
0.91% forward dividend yield and 10.37% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.06.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 22.29. meaning, the purchaser of the share is investing €22.29 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.37%.
yearly top and bottom value
vetoquinol's stock is valued at €90.50 at 17:30 est, way under its 52-week high of €113.80 and way higher than its 52-week low of €77.00.
dividend yield
as maintained by morningstar, inc., the next dividend payment is on jun 2, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.91%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vetoquinol's stock is considered to be overbought (>=80).
volatility
vetoquinol's last week, last month's, and last quarter's current intraday variation average was a negative 2.37%, a negative 0.70%, and a positive 1.16%.
vetoquinol's highest amplitude of average volatility was 2.79% (last week), 1.08% (last month), and 1.16% (last quarter).
more news about vetoquinol.
4. virbac (virp.pa)
0.49% forward dividend yield and 15.51% return on equity
virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.
earnings per share
as for profitability, virbac has a trailing twelve months eps of €14.39.
pe ratio
virbac has a trailing twelve months price to earnings ratio of 18.87. meaning, the purchaser of the share is investing €18.87 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.51%.
dividend yield
as stated by morningstar, inc., the next dividend payment is on jun 26, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.49%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, virbac's stock is considered to be overbought (>=80).
revenue growth
year-on-year quarterly revenue growth grew by 12.2%, now sitting on 1.22b for the twelve trailing months.
more news about virbac.